Orgenesis - Stock Price History | ORGS

Historical daily share price chart and data for Orgenesis since 2021 adjusted for splits. The latest closing stock price for Orgenesis as of October 27, 2021 is 4.76.
  • The all-time high Orgenesis stock closing price was 14.68 on March 15, 2018.
  • The Orgenesis 52-week high stock price is 8.30, which is 74.4% above the current share price.
  • The Orgenesis 52-week low stock price is 4.14, which is 13% below the current share price.
  • The average Orgenesis stock price for the last 52 weeks is 5.31.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Orgenesis Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 5.1679 4.5000 7.8400 2.7600 4.5000 -3.43%
2019 4.3166 4.9900 5.6000 2.6000 4.6600 -0.43%
2018 7.5502 13.8520 14.6800 3.8800 4.6800 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.114B $0.008B
Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing Organization and Cellular Therapy Business. Contract Development and Manufacturing Organization segment activity includes MaSTherCell, which specializes in cell therapy development for advanced medicinal products. Cellular Therapy Business segment activity is based on its technology which demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell like insulin producing cells for patients with Type 1 Diabetes. Orgenesis, Inc. is headquartered in Germantown, MD.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86